Regenxbio Inc.
Clinical trials sponsored by Regenxbio Inc., explained in plain language.
-
One-Shot gene therapy trial offers hope for boys with devastating muscle disease
Disease control Recruiting nowThis study is testing a one-time intravenous gene therapy called RGX-202 for boys with Duchenne muscular dystrophy (DMD). The goal is to see if delivering a new, functional gene to muscles is safe and can help slow or stop the progression of the disease. The study will enroll abo…
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Blood test could open door to future DMD gene therapies
Knowledge-focused Recruiting nowThis study aims to understand how many males with Duchenne muscular dystrophy (DMD) have certain antibodies in their blood. Researchers are screening up to 200 males aged 0 to 25 with DMD. The information will help identify who might be eligible for future gene therapy clinical t…
Sponsor: REGENXBIO Inc. • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:07 UTC